ClinicalTrials.gg
CompletedNCT04754100Updated Jun 6, 2023

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

A Phase 1 interventional study of agenT-797 in Relapsed/Refractory Multiple Myeloma, sponsored by MiNK Therapeutics. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-06.

Sponsored by MiNK Therapeutics (formerly part of Agenus Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2023, 3 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,168 studies in Multiple Myeloma with a site in United States — 275 open to participants now, 503 under way, 66 of them phase 3. Multiple Myeloma · United States.

Enrollment
1,496th of 1,901
13 · median 36
Started
2021
with 94 others
Phase 1
559 of 2,168
64 open now
Registered
1,707th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 1,496th largest by enrollment of the 1,901 interventional ones that give a count, is one of 95 that started in 2021, is one of 559 in phase 1, and was the 1,707th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

275 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in participants with relapsed or refractory multiple myeloma, as well as to define the recommended Phase 2 dose.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

Keywords

  • Multiple myeloma
  • Immunotherapy
  • iNKT cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Multiple Myeloma

    1. Confirmed diagnosis and evidence of progressive disease or clinical relapse as defined by International Myeloma Working Group criteria and following prior therapy for multiple myeloma (MM)
    2. Relapsed or refractory MM requiring current treatment
    3. Previously failed ≥ 3 prior regimens (after at least 2 cycles of medication per regimen) and included at least 1 immunomodulatory drug, 1 proteasome inhibitor, and an anti-CD38 antibody agent
    4. Participants must have as defined by at least 1 of the following:

      • Serum M-protein ≥ 0.5 grams/deciliter (dL) by serum protein electrophoresis or for immunoglobulin A (IgA) myeloma, by quantitative IgA; or
      • Urinary M-protein excretion at least 200 milligrams (mg)/24 hours; or
      • Serum free light chain whereby the involved light chain measures ≥ 10 mg/dL and with an abnormal ratio
  2. Estimated ≥ 3 months
  3. No other medical, surgical, or psychiatric condition (including active substance abuse) that would interfere with compliance to the protocol, as determined by the principal investigator

Key Exclusion Criteria:

  1. Concurrent invasive
  2. Participants who had an stem cell transplantation and are still on medications or above physiological dose within 4 weeks before agenT-797
  3. Prior radiotherapy within 2 weeks of start of study treatment
  4. Prior systemic cytotoxic chemotherapy, biological therapy, or major surgery within 3 weeks prior to dose of study drug
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Allogeneic iNKT Cells

    3+3 Dose escalation of agenT-797 will be administered by intravenous infusion every 2 weeks (each cycle is 14 days \[2 weeks\]).

    Drug: agenT-797

Interventions

  • agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.

06

What researchers measure

Primary outcomes

  1. Number Of Participants With Treatment-related Adverse Events

    This will be determined by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0.

    Time frame: Baseline through Day 28 post cell infusion

  2. Number Of Dose-limiting Toxicities

    Time frame: Baseline through Day 14 post cell infusion

Secondary outcomes

  1. Persistence Of agenT-797 In Peripheral Blood

    Time frame: Baseline/Day 1 (pre-infusion, 5 minutes, 0.25, 0,5, 1, 2, and 4 hours post cell infusion), Days 2, 3, 5, 8, 15, 22, and 29, Weeks 6, 8, and 12, and Months 6, 9, and 12

  2. Overall Response Rate (ORR)

    Time frame: End of study visit (up to 12 months)

  3. Duration Of Response (DOR)

    Time frame: End of study visit (up to 12 months)

  4. Duration Of Clinical Benefit

    Time frame: End of study visit (up to 12 months)

  5. Time To Response (TTR)

    Time frame: End of study visit (up to 12 months)

  6. Measurement Of Serum Alloantibodies To Major Histocompatibility Complex Class I And II

    Time frame: Baseline/Day 1 (pre-infusion), Day 22, Week 6, and end of study visit (up to 12 months)

07

Study locations

3 sites
  • Norton Cancer Institute - St. Matthews - Medical Oncology/Hematology Candida
    Louisville, Kentucky 40207, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Cincinnati Cancer Center
    Cincinnati, Ohio 45267, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jan 2023, 21 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 21 months is below that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2021
First posted
Feb 15, 2021
StartActual
Mar 29, 2021
Primary completionActual
Jan 13, 2023
CompletionActual
May 31, 2023
Last update
Jun 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04754100
Lead sponsor
MiNK Therapeutics
Responsible party
Sponsor
First posted
Feb 15, 2021
Start date
Mar 29, 2021
Primary completion
Jan 13, 2023
Completion
May 31, 2023
Last update
Jun 6, 2023

Study contacts

Medical Director
study director · MiNK Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Allogeneic Invariant Natural Killer T-cells agenT-797

Start the discussion